These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16461098)

  • 1. Simple graphic method for estimation of prostate-specific antigen doubling time.
    Sengupta S; Slezak JM; Blute ML; Bergstralh EJ
    Urology; 2006 Feb; 67(2):408-9. PubMed ID: 16461098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen doubling time as a predictor of Gleason grade in prostate cancer.
    Nowroozi MR; Zeighami S; Ayati M; Jamshidian H; Ranjbaran AR; Moradi A; Afsar F
    Urol J; 2009; 6(1):27-30. PubMed ID: 19241338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
    Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
    Semeniuk RC; Venner PM; North S
    Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
    Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
    Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival.
    Sengupta S; Blute ML; Bagniewski SM; Myers RP; Bergstralh EJ; Leibovich BC; Zincke H
    J Urol; 2006 May; 175(5):1684-90; discussion 1690. PubMed ID: 16600730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
    J Clin Oncol; 2007 May; 25(13):1765-71. PubMed ID: 17470867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A charting tool for estimating the PSA doubling time in patients with prostate cancer.
    Bellera CA; Hanley JA; Joseph L; Albertsen PC
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):315-6. PubMed ID: 16820269
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimal measure of PSA kinetics to identify prostate cancer.
    Benecchi L; Pieri AM; Destro Pastizzaro C; Potenzoni M
    Urology; 2008 Mar; 71(3):390-4. PubMed ID: 18342170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
    J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4.
    Daskivich TJ; Regan MM; Oh WK
    J Urol; 2006 Nov; 176(5):1927-37. PubMed ID: 17070213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Jpn J Clin Oncol; 2008 Jan; 38(1):36-42. PubMed ID: 18258713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: analysis on 56 cases of cancer-specific death.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Int J Urol; 2007 Feb; 14(2):123-7. PubMed ID: 17302568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer.
    Siemens DR; Heaton JP; Adams MA; Kawakami J; Graham CH
    Urology; 2009 Oct; 74(4):878-83. PubMed ID: 19476985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current applications for prostate-specific antigen doubling time.
    Ramírez ML; Nelson EC; Devere White RW; Lara PN; Evans CP
    Eur Urol; 2008 Aug; 54(2):291-300. PubMed ID: 18439749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen doubling time as a prognostic marker in prostate cancer.
    Eastham JA
    Nat Clin Pract Urol; 2005 Oct; 2(10):482-91. PubMed ID: 16474622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PSA doubling time and method of calculation].
    Ruffion A; Rebillard X; Grima F
    Prog Urol; 2005 Dec; 15(6):1035-41. PubMed ID: 16429649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
    Studer UE; Collette L; Whelan P; Albrecht W; Casselman J; de Reijke T; Knönagel H; Loidl W; Isorna S; Sundaram SK; Debois M;
    Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.